Prostate Cancer Survival Gains Spotlight ADT Cardiovascular Risks
Long-term cardiovascular consequences of androgen deprivation therapy (ADT) have emerged as an urgent clinical challenge for prostate cancer patients, according to Faisal Mehmud, MD, MRCP, a member of the Royal College of Physicians. As survival rates for prostate cancer improve, cardiovascular disease represents a major competing cause of morbidity and mortality. In some cases, more patients die from cardiovascular issues than from the cancer itself, Mehmud noted during an expert discussion with CancerNetwork.
Did you know? Cardiovascular disease is such a significant competing threat in prostate cancer management that patients frequently face higher mortality risks from heart complications than from the underlying oncology diagnosis, according to clinical insights shared by Dr. Faisal Mehmud.
Pathophysiological Mechanisms Driving Cardiovascular Morbidity
Testosterone suppression directly worsens body composition, insulin sensitivity, and lipid profiles, creating a complex metabolic syndrome environment. Beyond metabolic shifts, treatment-specific pathways play a critical role. According to Mehmud, GnRH agonists like leuprolide trigger an initial receptor stimulation that produces a transient testosterone and gonadotrophin surge before downregulation occurs. In contrast, GnRH antagonists block the receptor directly to avoid this initial surge. Preclinical findings suggest agonist signaling may influence vascular inflammation and plaque instability, though researchers continue to investigate these pathways. Additionally, profound androgen deprivation can cause QTc prolongation, a risk factor that clinicians must evaluate separately from standard atherosclerotic pathways.
GnRH Agonists vs. Antagonists: Evaluating Cardiovascular Equivalence
The mechanistic distinctions between agonists and antagonists center on initial receptor response and follicle-stimulating hormone (FSH) suppression. While agonists produce partial FSH suppression, antagonists deliver profound and sustained FSH suppression throughout the treatment course. Mehmud explained that this complete FSH suppression, paired with total testosterone suppression, may contribute to cardiovascular differentiation. Findings from the randomized phase 3/4 REVELUTION trial (NCT05320406), demonstrated significantly greater coronary plaque progression at one year in patients receiving leuprolide compared with those receiving a GnRH antagonist, despite similar testosterone suppression. This data challenges the long-held assumption that all forms of ADT are cardiovascularly equivalent.
Practical Frameworks for Pre-Treatment Risk Stratification
Clinicians must initiate cardiovascular risk conversations before prescribing hormonal therapy, rather than waiting for an adverse cardiac event to occur. Mehmud emphasized that risk stratification should prioritize men with established atherosclerotic cardiovascular disease—such as prior myocardial infarction, stroke, or heart failure—alongside patients managing diabetes, poorly controlled hypertension, dyslipidemia, chronic kidney disease, or a history of smoking. Prior to treatment selection, clinicians need a comprehensive assessment including blood pressure, lipid profiles, HbA1c levels, renal function, and current cardiovascular medications to ensure underlying conditions are optimally managed.
Pro Tip: Oncologists can easily manage foundational cardiovascular metrics without immediate cardiology access. Routinely track patient weight, measure blood pressure accurately, screen for smoking history, and review medications for potential QT-interval prolongation risks while maintaining active communication with the patient’s primary care physician.
Frequently Asked Questions
Why has cardiovascular risk received less attention than cancer control?
Historically, the immediate clinical priority rightly focused on direct disease control in advanced prostate cancer. However, as patient survival extends, competing cardiovascular risks in an older demographic have rightfully taken center stage.
What specific questions should patients ask their care teams?
Patients and caregivers should ask what their baseline cardiovascular risk is before treatment starts, whether the specific type of hormonal therapy impacts that risk, and how the clinical team plans to monitor heart health over the course of ADT.
Are all forms of ADT cardiovascularly equivalent?
Recent clinical trial data, such as the REVELUTION study, challenge this assumption by demonstrating significantly greater coronary plaque progression with leuprolide compared to a GnRH antagonist.
Next Steps in Clinical Evidence and Future Trials
Establishing GnRH antagonists as the preferred option for high-risk patients requires prospective, randomized trial data utilizing novel surrogate endpoints. Mehmud confirmed that researchers have reached agreement with the FDA on a new study design utilizing coronary plaque volume to accelerate the evaluation of cardiovascular differentiation with emerging GnRH antagonists, such as Teverelix trifluoroacetate (Teverelix TFA).
Join the Conversation: How is your clinical practice addressing the intersection of oncology and cardiology? Share your thoughts in the comments below, explore our related articles on cardio-oncology, and subscribe to our newsletter for the latest updates in cancer care.
Related reading